3.3
CiteScore
41 days
Time to First Decision

Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.

Journal of Market Access & Health Policy, Volume 1, Issue 1

2013 January - 6 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

Select all

Article

61 Citations

924 Views

20 Pages

Drug Reformulations and Repositioning in Pharmaceutical Industry and Its Impact on Market Access: Reassessment of Nomenclature

Susana Murteira,
Zied Ghezaiel,
Slim Karray and
Michel Lamure

J. Mark. Access Health Policy2013, 1(1), 21131;https://doi.org/10.3402/jmahp.v1i0.21131

6 August 2013

Background: Medicinal products that have been developed and approved for one disease may be the object of additional clinical development in other disease areas or of additional pharmaceutical development for new and different formulations. The newly...

Full Article

Article

38 Citations

547 Views

6 Pages

Benefits of Probabilistic Sensitivity Analysis—A Review of NICE Decisions

Erpur Adalsteinsson and
Mondher Toumi

J. Mark. Access Health Policy2013, 1(1), 21240;https://doi.org/10.3402/jmahp.v1i0.21240

6 August 2013

Objective: Since 2004, the National Institute of Health and Clinical Excellence (NICE) has required manufacturers to conduct a probabilistic sensitivity analysis (PSA) in their technology appraisals. The objective of this review is to assess the cost...

Full Article

Article

401 Views

2 Pages

Delay and Restricted Access of New Molecules in Turkey Compared to the United States and European Union

Toros Şahin,
Atakan Yeşil and
Türker Topcu

J. Mark. Access Health Policy2013, 1(1), 22799;https://doi.org/10.3402/jmahp.v1i0.22799

15 November 2013

Objective: This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007–2013. Methods: The Thomson Reuters Newport Horizon for Innovators Database is used to identi...

Full Article

Article

10 Citations

448 Views

6 Pages

New Drug Regulations in France: What Are the Impacts on Market Access? Part 2—Impacts on Market Access and Impacts for the Pharmaceutical Industry

Cécile Rémuzat,
Mondher Toumi and
Bruno Falissard

J. Mark. Access Health Policy2013, 1(1), 20892;https://doi.org/10.3402/jmahp.v1i0.20892

6 August 2013

Access to the French drug market is being impacted by an ongoing dramatic shift in practice as well as by two laws that came into force in December 2011. This new environment has been described and analyzed in two separate articles. This second artic...

Full Article